Form 4: Mirum CEO Peetz Boosts Stake with New Equity Awards

Mirum Pharmaceuticals CEO Christopher Peetz reported significant equity awards, including stock options, restricted stock units, and performance-based units, on January 28, 2026.

Summary

• Christopher Peetz, Chief Executive Officer and Director of Mirum Pharmaceuticals, Inc. (MIRM), reported the acquisition of various derivative securities on January 28, 2026.
• Acquired 67,000 stock options with an exercise price of $100.85, vesting over approximately four years starting one year after January 28, 2026, and expiring on January 27, 2036.
• Acquired 43,500 Restricted Stock Units (RSUs), vesting in three equal annual installments on each anniversary of January 28, 2026.
• Acquired 75,000 Performance Restricted Stock Units (PSUs), which were granted on January 23, 2024, and for which performance criteria were determined to have been met on January 28, 2026. These PSUs vest 2/3 on March 15, 2026, and 1/3 on March 15, 2027.
• The total number of derivative securities beneficially owned following these transactions is 67,000 stock options, 43,500 RSUs, and 75,000 PSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting continued executive commitment and the achievement of performance milestones, which can instill confidence in the company's leadership and strategic direction.

Positives

• Significant equity awards granted to the CEO, aligning his interests with long-term shareholder value.
• The vesting schedules for stock options and RSUs encourage sustained performance over several years.
• Performance criteria for PSUs were met, indicating the achievement of specific company goals.

Future Outlook

The vesting schedules for the equity awards extend several years into the future, indicating a long-term commitment from the CEO to the company's performance and growth. The achievement of performance criteria for PSUs suggests positive progress on specific company objectives.

Industry Context

StockSavvy.ai notes that significant equity grants to a CEO are a common practice in the biotechnology and pharmaceutical industry, often used to incentivize long-term leadership and align executive compensation with shareholder returns. The structure, including performance-based units, reflects a trend towards tying executive pay to specific operational and strategic achievements.

Stakeholder Impact

• Shareholders: The equity awards align the CEO's financial interests with long-term shareholder value creation, potentially leading to increased confidence in management.
• Employees: The compensation structure for the CEO may set a precedent or reflect the company's overall approach to incentivizing performance.

Next Steps

• Vesting of 1/4th of stock options one year after January 28, 2026, followed by 36 successive equal monthly installments.
• Vesting of 1/3rd of Restricted Stock Units on each anniversary of January 28, 2026, for three years.
• Vesting of 2/3 of Performance Restricted Stock Units on March 15, 2026.
• Vesting of 1/3 of Performance Restricted Stock Units on March 15, 2027.

Key Dates

Recommendation

While this Form 4 indicates strong insider alignment and achievement of performance goals, which are positive signals, it primarily reports executive compensation. A seasoned investor would typically not make a 'buy' or 'sell' decision solely based on an executive's equity grant, but rather consider it as one factor among broader financial performance, market conditions, and strategic outlook. The grants reinforce a 'hold' stance for existing investors, indicating stability and management commitment.

Keywords

Mirum Pharmaceuticals, MIRM, Christopher Peetz, CEO, Director, Stock Option, Restricted Stock Units, Performance Stock Units, Equity Award, Insider Transaction, Compensation, Vesting, SEC Form 4